Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

This integration evolves Noom’s comprehensive approach to weight management by enabling a streamlined solution for members ...

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today. The company’s shares closed last ...

Eli Lilly (LLY) closed the most recent trading day at $825.91, moving +0.41% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.55%. Meanwhile, the ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

In an exclusive interview with NBC News, President Donald Trump said there were methods that would allow him to seek a third term in the White House.

The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read ...

The PGIM Jennison Rising Dividend Fund declined for Q4 2024 and underperformed the 2.4% return of the S&P 500 Index. Click ...